BR112021017529A2 - Composições de matéria com atividade para remover a lipofuscina a partir das células da retina - Google Patents

Composições de matéria com atividade para remover a lipofuscina a partir das células da retina

Info

Publication number
BR112021017529A2
BR112021017529A2 BR112021017529A BR112021017529A BR112021017529A2 BR 112021017529 A2 BR112021017529 A2 BR 112021017529A2 BR 112021017529 A BR112021017529 A BR 112021017529A BR 112021017529 A BR112021017529 A BR 112021017529A BR 112021017529 A2 BR112021017529 A2 BR 112021017529A2
Authority
BR
Brazil
Prior art keywords
compositions
retinal cells
activity
matter
lipofuscin
Prior art date
Application number
BR112021017529A
Other languages
English (en)
Portuguese (pt)
Inventor
Rodriguez BOULAN Enrique
M Nociari Marcelo
Original Assignee
Univ Cornell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cornell filed Critical Univ Cornell
Publication of BR112021017529A2 publication Critical patent/BR112021017529A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BR112021017529A 2019-03-05 2020-03-03 Composições de matéria com atividade para remover a lipofuscina a partir das células da retina BR112021017529A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962814028P 2019-03-05 2019-03-05
PCT/US2020/020805 WO2020180872A1 (en) 2019-03-05 2020-03-03 Compositions of matter with activity to remove lipofuscin from retinal cells

Publications (1)

Publication Number Publication Date
BR112021017529A2 true BR112021017529A2 (pt) 2021-11-09

Family

ID=72337111

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021017529A BR112021017529A2 (pt) 2019-03-05 2020-03-03 Composições de matéria com atividade para remover a lipofuscina a partir das células da retina

Country Status (16)

Country Link
US (1) US20220118002A1 (https=)
EP (1) EP3934660A4 (https=)
JP (1) JP7573881B2 (https=)
KR (1) KR20210142651A (https=)
CN (1) CN113747902A (https=)
AU (1) AU2020232266A1 (https=)
BR (1) BR112021017529A2 (https=)
CA (1) CA3132466A1 (https=)
CO (1) CO2021012267A2 (https=)
EA (1) EA202192183A1 (https=)
IL (1) IL286002A (https=)
MX (1) MX2021010650A (https=)
PH (1) PH12021552131A1 (https=)
SG (1) SG11202109541YA (https=)
WO (1) WO2020180872A1 (https=)
ZA (1) ZA202106559B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3205822A1 (en) * 2021-01-22 2022-07-28 Marcelo M. NOCIARI Compositions and methods for the identification of compounds that protect against lipofuscin cytotoxicity
AU2023420130A1 (en) * 2022-12-30 2025-08-14 Cornell University Acid cyclodextrins for the treatment of lipofuscin buildups and ocular diseases
CN116253809B (zh) * 2023-04-19 2024-11-05 广州润虹医药科技股份有限公司 一种去除壳聚糖中内毒素的方法
WO2025147228A1 (en) * 2024-01-02 2025-07-10 Alkeus Pharmaceuticals, Inc. Treatment for asymptomatic stargardt disease patients with gildeuretinol acetate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
US8679511B2 (en) * 2009-10-01 2014-03-25 Duquesne University of the Holy Spririt In-situ gel ophthalmic drug delivery system of estradiol or other estrogen for prevention of cataracts
WO2011072141A1 (en) * 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
US10463687B2 (en) * 2011-01-20 2019-11-05 Cornell University Treatments for retinal disorders
KR101423631B1 (ko) * 2012-08-17 2014-07-25 주식회사파마킹 에스-알릴엘-시스테인을 유효성분으로 포함하는 안질환 예방 또는 치료용 조성물 및 이를 포함하는 의약제제
WO2014152959A1 (en) * 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
WO2016168772A1 (en) 2015-04-17 2016-10-20 Sens Research Foundation, Inc. Cyclodextrin compounds for the prevention and treatment of aging
GB2556082A (en) 2016-11-18 2018-05-23 Warneford Healthcare Ltd Ophthalmic composition

Also Published As

Publication number Publication date
EP3934660A4 (en) 2022-11-23
JP7573881B2 (ja) 2024-10-28
WO2020180872A1 (en) 2020-09-10
CA3132466A1 (en) 2020-09-10
PH12021552131A1 (en) 2022-08-22
KR20210142651A (ko) 2021-11-25
CN113747902A (zh) 2021-12-03
US20220118002A1 (en) 2022-04-21
EP3934660A1 (en) 2022-01-12
EA202192183A1 (ru) 2022-01-14
ZA202106559B (en) 2025-01-29
IL286002A (en) 2021-10-31
JP2022525007A (ja) 2022-05-11
AU2020232266A1 (en) 2021-09-23
SG11202109541YA (en) 2021-09-29
MX2021010650A (es) 2021-12-10
CO2021012267A2 (es) 2021-10-20

Similar Documents

Publication Publication Date Title
BR112021017529A2 (pt) Composições de matéria com atividade para remover a lipofuscina a partir das células da retina
Delplace et al. Delivery strategies for treatment of age-related ocular diseases: From a biological understanding to biomaterial solutions
BR112014027571A2 (pt) métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas
WO2012158910A3 (en) Compositions and methods for treating retinal diseases
BR112017014332A2 (pt) métodos de tratamento de doenças retinianas
WO2014144932A3 (en) Methods of using zscan4 for rejuvenating human cells
MX2009010988A (es) Uso de trans-carotenoides bipolares como un tratamiento previo y en el tratamiento de una enfermedad vascular periferica.
AR088585A1 (es) Un medicamento para tratar la enfermedad del ojo anterior
Mashor et al. Keratoconus caused by eye rubbing in patients with Tourette syndrome
Kunert et al. One-year results of small incision lenticule extraction (SMILE) in myopia
WO2015048188A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders
CO2019012336A2 (es) Métodos y composiciones para tratar enfermedades asociadas a la retina mediante inhibidores de ccr3
Manzano-Gayosso et al. Mycotic keratitis in an eye care hospital in Mexico City
MX2023008613A (es) Composiciones y metodos para la identificacion de compuestos que protegen contra la citotoxicidad de la lipofuscina.
WO2017152129A3 (en) Treatment of glaucoma and/or retinal diseases and formulations useful therefore
WO2023133058A3 (en) Compositions and methods used for retinal ischemia or diabetes
Mark et al. Modulatory effect of different riboflavin compositions on the central corneal thickness of African keratoconus corneas during collagen crosslinking
MX350201B (es) Composiciones oftalmicas con ceras alcoxiladas naturales.
BR112019000059A2 (pt) tratamento de doença vascular da retina com o uso de células progenitoras
MX2016013741A (es) Rápido alivio de las fluctuaciones motoras en la enfermedad de parkinson.
DT Osteo-odonto keratoprosthesis in Stevens-Johnson syndrome: a case report
VITAMINS et al. D. Stasytytė-Bunevičienė
Lucas et al. Oxidative stress in human aortas from occlusive and aneurysmal diseases
Carlos E et al. Plus disease: Why is it important in retinopathy of prematurity?
Maruyama Deepening of the upper eyelid sulcus: case report

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements